Comparative Pharmacology
Head-to-head clinical analysis: CRESTOR versus PITAVASTATIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESTOR versus PITAVASTATIN CALCIUM.
CRESTOR vs PITAVASTATIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, reducing cholesterol synthesis in the liver and increasing LDL receptor expression.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
1-4 mg orally once daily
None Documented
None Documented
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
The terminal elimination half-life is approximately 12 hours (range 9–16 hours), supporting once-daily dosing.
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Approximately 79% of the dose is excreted in feces (as parent drug and metabolites) via biliary elimination, and about 15% is excreted in urine. Less than 2% is excreted unchanged in urine.
Category C
Category D/X
Statin
Statin